Dr. Cem Akin, MD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 64
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
MI license 4301082935 · MA license 241209 -
Internal Medicine Physician
MA license 241209 · MI license 4301082935
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 64
- Services billed
- 292
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 25 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xolair (omalizumab) | 53 |
| Fluticasone Propionate Other prescribers in Northville, MI | 33 |
| Montelukast Sodium Other prescribers in Northville, MI | 30 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Northville, MI | 19 |
| Epinephrine Other prescribers in Northville, MI | 18 |
| Famotidine Other prescribers in Northville, MI | 18 |
| Dupixent Pen (dupilumab) Other prescribers in Northville, MI | 16 |
| Azelastine Hcl Other prescribers in Northville, MI | 16 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 14 |
| Ayvakit (avapritinib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $9,416 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,400 |
|---|---|
| Sanofi US Services Inc. | $2,355 |
| Blueprint Medicines Corporation | $2,148 |
| Cycle Pharmaceuticals Inc | $1,560 |
| Tersera Therapeutics LLC | $953 |
| Consulting Fee | $7,268 |
|---|---|
| Honoraria | $2,142 |
| Food and Beverage | $6.15 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Mar 17, 2025 | Consulting Fee | $2,400 |
| Sanofi US Services Inc. Nov 21, 2025 | Consulting Fee AYVAKIT · Gastroenterology | $2,355 |
| Blueprint Medicines Corporation May 23, 2025 | Honoraria | $2,142 |
| Cycle Pharmaceuticals Inc Sep 16, 2025 | Consulting Fee Cromolyn Sodium · Pulmonary/Respiratory Diseases | $1,560 |
| Tersera Therapeutics LLC Dec 10, 2025 | Consulting Fee Quzyttir · Acute Care | $953 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $497,312 in research payments for these studies, mostly to the institutions running them.
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation · Active, not recruiting · NCT03731260 - A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Blueprint Medicines Corporation - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Sanofi US Services Inc. · Recruiting · NCT04910685
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.